Publications by authors named "T Sueda"
Purpose: Sentinel lymph node biopsy (SLNB) can detect occult nodal metastasis. We have previously reported the safety and feasibility of indocyanine green (ICG)-guided SLNB for clinical stage II/III lower rectal cancer (RC). However, little is known about the influence of lateral pelvic SLNB using ICG on oncological outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the importance of the lymph node ratio (LNR) in determining prognosis for patients with ampullary cancer who underwent surgical treatment between 1980 and 2018.
- Analysis of data from 106 patients revealed that higher LNR values correlated with worse outcomes, specifically linking a higher LNR to increased recurrence and lower survival rates.
- Findings suggest that LNR, particularly with an identified cut-off value of 0.07, serves as a critical independent prognostic marker for recurrence and survival in ampullary cancer patients.
Article Synopsis
- - This study focuses on the impact of dysphagia (difficulty swallowing) in patients with advanced esophageal cancer, particularly those who are eligible for surgery after preoperative treatment.
- - Researchers analyzed data from 302 patients and found that higher dysphagia scores were linked to worse tumor characteristics, lower body mass index, and poorer overall survival rates.
- - The results indicate that dysphagia scores can serve as an independent prognostic factor for overall survival post-surgery, with higher scores correlating to increased recurrence rates and lower survival outcomes.
Article Synopsis
- Identifying patients who won't benefit from invasive pancreatic cancer surgery is important to preserve quality of life, especially after neoadjuvant therapy for resectable cases.
- The study analyzed 609 patients, categorizing them into poor-prognosis (those with rapid recurrence or no surgery) and good-prognosis groups (those without recurrence or longer recurrence intervals).
- Key findings showed that elevated levels of carbohydrate antigen 19-9 (specifically >200 U/mL) after treatment were strongly linked to poor survival rates, indicating that patients with such levels should avoid radical surgery due to low chances of benefit.
Pembrolizumab plus chemotherapy has been indicated as the first-line treatment for metastatic or unresectable locally advanced esophageal cancer. However, pretreatment biomarkers for predicting clinical outcomes remain unclear. We investigated the predictive value of inflammation-based prognostic scores in patients treated with pembrolizumab and chemotherapy.
View Article and Find Full Text PDF